Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)
About the study
The purpose of this randomized study is to assess safety and effectiveness of BMS-986263 in adults with compensated cirrhosis (chronic liver disease) from nonalcoholic steatohepatitis (fatty liver disease) (NASH).
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Participants with liver biopsy fibrosis score stage 4 (NASH CRN) performed within 12 months
- Men and women must agree to follow methods of contraception
EXCLUSION CRITERIA
Exclusion Criteria:
- Worsening liver disease or any disease might compromise participant safety in the opinion of the investigator
- Known immunocompromised status or any disease or condition which might compromise participant safety
- Prior exposure to BMS-986263
- Clinically relevant abnormal physical examination, vital signs, ECG, or clinical laboratory tests
- Hepatic decompensation
Other protocol-defined inclusion/exclusion criteria apply
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Nonalcoholic Steatohepatitis (NASH)
Age (in years)
21 - 75
Phase
Phase 2
Participants needed
124
Est. Completion Date
Dec 28, 2026
Treatment type
Interventional
Sponsor
Bristol-Myers Squibb
ClinicalTrials.gov identifier
NCT04267393
Study number
IM025017
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?